Ruth E Cooper1, Charlotte Tye2, Jonna Kuntsi2, Evangelos Vassos2, Philip Asherson2. 1. King's College London, MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, London London, UK ruth.cooper@kcl.ac.uk. 2. King's College London, MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, London London, UK.
Abstract
BACKGROUND: Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are promoted as cognitive enhancers with consumption recommended in the general population and those with neurocognitive deficits such as attention deficit hyperactivity disorder (ADHD). However, evidence from randomised placebo-controlled trials is inconclusive. AIMS: This study aimed to conduct a systematic review and meta-analysis examining the effect of n-3 PUFA supplementation on cognition in healthy populations and those with ADHD and related disorders (RDs). METHODS: Databases were searched for randomised controlled trials (RCTs) in adults and school-aged children (who were healthy and typically developing (TD) or had ADHD or a related-neurodevelopmental disorder (ADHD+RD) which assessed the effects of n-3 PUFA on cognition. RESULTS: In the 24 included studies n-3 PUFA supplementation, in the whole sample and the TD and ADHD+RD subgroup, did not show improvements in any of the cognitive performance measures. In those with low n-3 PUFA status, supplementation improved short-term memory. CONCLUSIONS: There is marginal evidence that n-3 PUFA supplementation effects cognition in those who are n-3 PUFA deficient. However, there is no evidence of an effect in the general population or those with neurodevelopmental disorders. This has important implications given the widespread advertisement and consumption of n-3 PUFA; claims of cognitive benefit should be narrowed.
BACKGROUND:Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are promoted as cognitive enhancers with consumption recommended in the general population and those with neurocognitive deficits such as attention deficit hyperactivity disorder (ADHD). However, evidence from randomised placebo-controlled trials is inconclusive. AIMS: This study aimed to conduct a systematic review and meta-analysis examining the effect of n-3 PUFA supplementation on cognition in healthy populations and those with ADHD and related disorders (RDs). METHODS: Databases were searched for randomised controlled trials (RCTs) in adults and school-aged children (who were healthy and typically developing (TD) or had ADHD or a related-neurodevelopmental disorder (ADHD+RD) which assessed the effects of n-3 PUFA on cognition. RESULTS: In the 24 included studies n-3 PUFA supplementation, in the whole sample and the TD and ADHD+RD subgroup, did not show improvements in any of the cognitive performance measures. In those with low n-3 PUFA status, supplementation improved short-term memory. CONCLUSIONS: There is marginal evidence that n-3 PUFA supplementation effects cognition in those who are n-3 PUFA deficient. However, there is no evidence of an effect in the general population or those with neurodevelopmental disorders. This has important implications given the widespread advertisement and consumption of n-3 PUFA; claims of cognitive benefit should be narrowed.
Authors: Natalie C Fortune; Emily W Harville; Jack M Guralnik; Jeanette Gustat; Wei Chen; Lu Qi; Lydia A Bazzano Journal: Am J Clin Nutr Date: 2019-06-01 Impact factor: 7.045
Authors: Joseph Firth; Scott B Teasdale; Kelly Allott; Dan Siskind; Wolfgang Marx; Jack Cotter; Nicola Veronese; Felipe Schuch; Lee Smith; Marco Solmi; André F Carvalho; Davy Vancampfort; Michael Berk; Brendon Stubbs; Jerome Sarris Journal: World Psychiatry Date: 2019-10 Impact factor: 49.548
Authors: Lizanne J S Schweren; Daan van Rooij; Huiqing Shi; Henrik Larsson; Alejandro Arias-Vasquez; Lin Li; Liv Grimstvedt Kvalvik; Jan Haavik; Jan Buitelaar; Catharina Hartman Journal: Nutrients Date: 2021-05-11 Impact factor: 5.717
Authors: Graham Mazereeuw; Nathan Herrmann; Paul I Oh; David W L Ma; Cheng Tao Wang; Alexander Kiss; Krista L Lanctôt Journal: J Clin Psychopharmacol Date: 2016-10 Impact factor: 3.153